Search

Displaying results 3221 - 3230 of 8974 in total
  1. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.

  2. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    It has been used for stimulation of biliary lipid secretion. The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  3. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Cost of the drug and patient aversion to the taste of Vayarin were significant reasons for therapy failure [L1502].

  4. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.

  5. Drug

    Fluorouracil

    go.drugbank.com/drugs/DB00544
    ApprovedInvestigational

    It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

  6. Drug

    Norelgestromin

    go.drugbank.com/drugs/DB06713
    ApprovedInvestigational

    [L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.

    Mixtures: Gwyn LoCategories: Hormonal Contraceptives for Systemic Use
  7. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter … By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency.

  8. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  9. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  10. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

    Categories: Antihypertensive Agents Indicated for Hypertension